Home > Urology > EAU 2020 > Renal Cancer > Debate: upfront cytoreductive nephrectomy or not?

Debate: upfront cytoreductive nephrectomy or not?

Presented By
Prof. Axel Bex & Prof. Antonio Finelli
Conference
EAU 2020
Trial
Phase 3, CARMENA; SURTIME
The EAU20 virtual meeting featured a thematic session looking at the controversy in renal cancer surgery considering the timing and necessity of cytoreductive nephrectomy. Prof. Axel Bex (The Royal Free London NHS Foundation Trust, UK) argued that cytoreductive nephrectomy should only be performed in selected patients after systemic treatment [1]. The counterpoint was provided by Prof. Antonio Finelli (University Health Network, Canada) who argued in favour of upfront cytoreductive nephrectomy [2]. Prof. Bex commenced his debate by stressing that his arguments only apply to patients who require systemic therapy, such as those diagnosed with metastatic renal cell carcinoma (mRCC). There is evidence from 2 trials investigating the role and sequence of cytoreductive nephrectomy. The CARMENA trial randomised 450 patients eq...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on